Clinical trials: High Risk for Breast Cancer
Triple Negative Breast Cancer, Breast Cancer
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
The purpose of this study is to compare the efficacy and safety between docetaxel combined with doxorubicin (epirubicin) and cyclophosphamide followed by gemcitabine combined with cisplatin and doxorubicin (epirubicin) combined…
- Trial name
- NCT02641847
- Testing
- docetaxel, doxorubicin or epirubicin, cyclophosphamide
- Where
- China
- Volunteers
- 503 people
- Sponsor
- Fudan University
Breast Cancer
Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Peripheral stem cell transplantation combined with biological therapy may be an effective treatment for breast…
- Trial name
- NCT00002616
- Testing
- aldesleukin, filgrastim, carboplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Illinois at Chicago
Hodgkin Disease, Breast Cancer
Personalised Program for Women Treated for Hodgkin Disease
After treatment for Hodgkin disease, secondary cancer, in particular breast cancer induced by treatment, are the first cause of death.
- Trial name
- PROPER (NCT01188915)
- Testing
- intensive screening
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer
The study was designed to investigate whether hypofractionated adjuvant radiotherapy is noninferior to conventionally fractionated adjuvant radiotherapy in terms of efficacy and toxicities for high risk breast cancer patients…
- Trial name
- NCT03856372
- Testing
- Hypofractionated, Conventional
- Where
- 3 sites in China
- Volunteers
- 1,494 people
- Sponsor
- Fudan University
Fatigue
Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer
This is a parallel-track, randomized study will observe whether intravenous ascorbic acid reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer.
- Trial name
- NCT02521077
- Testing
- Ascorbic Acid, Normal Saline
- Sponsor
- Midwestern Regional Medical Center
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT03323658
- Testing
- Bexarotene, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）
This study is a Phase III non-inferiority trial targeting a specific subset of early breast cancer patients: those with HR-positive/HER2-negative, node-negative small tumors (typically ≤2cm) but who exhibit high-risk features for…
- Trial name
- NCT07432178
- Testing
- Dalpiciclib+AI ± OFS, TC (Docetaxel + Cyclophosphamide) × 4 cycles- endocrine therapy
- Where
- China
- Volunteers
- 2,288 people
- Sponsor
- Fudan University
Breast Cancer
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone plus AC versus Docetaxel plus AC as neoadjuvant chemotherapy in high-risk HER2-negative early-stage or locally advanced breast cancer.
- Trial name
- NCT05673629
- Testing
- Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC
- Where
- China
- Volunteers
- 552 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Breast Cancer Stage IV
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
After an initial screening phase (SAFIR 03 - SCREENING) to identify patients with blood circulating mutated-PIK3CA tumours persistent, patients will be enrolled in the treatment phase of SAFIR 03 (SAFIR 03 - ARRIBA) that was…
- Trial name
- SAFIR 03 (NCT05625087)
- Testing
- Alpelisib, Ribociclib
- Where
- 44 sites in France
- Volunteers
- 4 people
- Sponsor
- UNICANCER
Breast Cancer
MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick
Accurate risk assessment is essential for the success of population screening programs and early detection efforts in breast cancer. Mirai is a new deep learning model based on full resolution mammograms.
- Trial name
- NCT05968157
- Testing
- Breast MRI, MIRAI
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- University of Massachusetts, Worcester
Breast Adenocarcinoma, Estrogen Receptor Negative
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer.
- Conditions
- Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT02488967
- Testing
- Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 1,296 sites in United States, Canada
- Volunteers
- 782 people
- Sponsor
- NRG Oncology
Breast Cancer
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01547741
- Testing
- Doxorubicin, Cyclophosphamide, Docetaxel
- Where
- 915 sites in United States, Puerto Rico
- Volunteers
- 4,242 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer
An open clinical trial not randomized, multicentric. This study search to evaluate vitamin D supplementation efficacy at high dose (UVEDOSE, colecalciferol, oral solution at 100 000 UI) of vitamin D on day 1 of each cycles for…
- Trial name
- OPTIVIT (NCT04091178)
- Testing
- VITAMIN D
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer
Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
- Trial name
- NCT00285857
- Testing
- Lovastatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Breast Cancer, Tear
Tear Based Sample Collection Breast Cancer Detection
This study aims to collect tear samples from 50 women who have been recently diagnosed with breast cancer.
- Conditions
- Breast Cancer, Tear, Breast Cancer Female
- Trial name
- NCT04974567
- Testing
- Schirmer Strip
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Namida Lab
Breast Cancer
Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer
This research study is comparing Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) to MRI as a screening tool for breast cancer.
- Trial name
- NCT02275871
- Testing
- MRI, CESM
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer.
- Trial name
- NCT06797635
- Testing
- Patritumab deruxtecan, Pembrolizumab, Paclitaxel
- Where
- 17 sites in United States, South Korea and 2 more
- Volunteers
- 372 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Neoplasm, Neoplasm Metastasis
Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer
This study will evaluate the effectiveness of combination chemotherapy with paclitaxel (Taxol) and cyclophosphamide (Cytoxan), followed by high-dose melphalan and etoposide for treating inflammatory breast cancer.
- Trial name
- NCT00001507
- Testing
- Monoclonal Antibody 3A1, Monoclonal Antibody 95-5-49, Monoclonal Antibody 95-6-22
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Breast Cancer
Cancer Screening and Prevention Program for High Risk Women
The purpose of this study is to collect information from a large group of women who may have a greater chance to develop cancer because of their own personal history of cancer or because of their family history of cancer.
- Trial name
- NCT00849199
- Where
- 3 sites in United States
- Volunteers
- 1,452 people
- Sponsor
- NYU Langone Health
Breast Cancer, Ductal Carcinoma
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia
- Trial name
- BabyTEARS (NCT07499999)
- Testing
- Exemestane, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute